BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...tiered royalties.RhoVac reports positive Phase I/II data for vaccine against prostate cancer recurrenceSwedish biotech RhoVac AB (AktieTorget:RHOVAC...
Items per page:
1 - 1 of 1
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...tiered royalties.RhoVac reports positive Phase I/II data for vaccine against prostate cancer recurrenceSwedish biotech RhoVac AB (AktieTorget:RHOVAC...
Items per page:
1 - 1 of 1